Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Agarwal, R; Anker, SD; Bakris, G; Filippatos, G; Pitt, B; Rossing, P; Ruilope, L; Gebel, M; Kolkhof, P; Nowack, C; Joseph, A, , FIDELIO-DKD, and, FIGARO-DKD, Investigators.
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Nephrol Dial Transplant. 2022; 37(6):1014-1023 Doi: 10.1093/ndt/gfaa294 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Study Group Mitglieder der Med Uni Graz:
Sourij Harald

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).
Find related publications in this database (using NLM MeSH Indexing)
Animals - administration & dosage
Diabetes Mellitus, Type 2 - complications, drug therapy
Diabetic Nephropathies - drug therapy
Humans - administration & dosage
Mineralocorticoid Receptor Antagonists - therapeutic use
Naphthyridines - administration & dosage
Quality of Life - administration & dosage
Renal Dialysis - administration & dosage
Renal Insufficiency, Chronic - chemically induced, complications, drug therapy

Find related publications in this database (Keywords)
clinical trial
diabetic kidney disease
mineralocorticoid receptor antagonist
© Med Uni Graz Impressum